Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on August 8, 2009
Japanese Journal of Clinical Oncology 2009 39(11):751-755; doi:10.1093/jjco/hyp085
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/11/751    most recent
hyp085v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Seki, Y.
Right arrow Articles by Ueno, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seki, Y.
Right arrow Articles by Ueno, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Four Cases of Pancreatic Acinar Cell Carcinoma Treated with Gemcitabine or S-1 as a Single Agent

Yoshitaka Seki1, Takuji Okusaka1, Masafumi Ikeda1,2, Chigusa Morizane1 and Hideki Ueno1

1 Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo
2 Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

For reprints and all correspondence: Yoshitaka Seki, Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: yoseki{at}ncc.go.jp

Received March 30, 2009; accepted June 29, 2009

Pancreatic acinar cell carcinoma (ACC) is a comparatively rare tumor and account for ~1% of all cases of pancreatic cancer. Clinical presentation is usually related to either local spread or metastasis. The clinical features, especially those related to the prognosis and treatment outcomes, have not yet been fully clarified. There are no established treatments for unresectable pancreatic ACC. We administered gemcitabine monotherapy to four patients with ACC; however, the results were not satisfactory. Disease control without obvious tumor shrinkage was observed in one patient. Another patient showed severe renal damage caused by gemcitabine. On the other hand, fluoropyrimidine-based chemotherapy may have some activity against this tumor, because one of the three patients who received S-1 as second-line chemotherapy showed a partial response. Prospective clinical trials are necessary to confirm the effectiveness of fluoropyrimidine for the treatment of pancreatic ACC.

Key Words: GI-pancreas • GI-pancreas-med • GI-pancreas-radoncol • chemo-GI tract


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.